: Senesco Technologies, Inc. Joel Brooks Chief Financial Officer jbrooks@senesco.com (732) 296-8400 FD Brian Ritchie brian.ritchie@fd.com 212-850-5600 Senesco Tec

Senesco Technologies Reports Fiscal Year 2009 Financial Results

NEW BRUNSWICK, N.J. (September 29, 2009) - Senesco Technologies,

Inc. ("Senesco" or the

"Company") (NYSE Amex: SNT) reported financial results for the fiscal year ended

June 30, 2009 ("Fiscal 2009").

Net loss for Fiscal 2009 was $5.7

million, or $0.30 per share, compared with a net loss of $4.6 million, or $0.26

per share, for the fiscal year ended June 30, 2008 ("Fiscal

2008"). The increase in net loss was primarily the result of an

increase of approximately $0.6 million in human health research and development

expenses related to the development of the Company's multiple myeloma therapy,

SNS-01, and an increase of

approximately $0.6 million in non-cash expenses associated with the outstanding

convertible notes that were issued during Fiscal 2008.

Fiscal 2009 and Recent

Bruce Galton, President and Chief

Executive Officer of the Company, said, "We have continued to build Senesco by

generating additional preclinical data in multiple myeloma for

SNS-01, closing additional funding and adding Harlan W. Waksal, M.D. and

Warren W. Isabelle, CFA to our Board. Our primary focus continues to be

Investigational New Drug application for SNS-01."

Revenue of $275,000 for Fiscal 2009

consisted of milestone payments in connection with certain agricultural license

agreements. During Fiscal 2008, the Company reported

revenue in the amount of $456,667, which consisted of initial fees and milestone payments

related to Senesco's agricultural development and license

Research and development expenses during

Fiscal 2009 were $2.4 million, compared with $1.8 million during Fiscal 2008, an

increase of approximately 33%. This increase resulted primarily

from the expansion of Senesco's human health

programs; specifically the

Company's multiple myeloma project, which was partially offset by a decrease in

the cost of Senesco's research agreement with the University of Waterloo. The Company expects research and development

expenses to continue to increase as it expands its research activities,

particularly in the area of multiple myeloma.

General and administrative expenses were

$2.2 million during Fiscal 2009, compared with $2.3 million during Fiscal 2008,

a decrease of about 4%. This slight decrease was primarily due to a

decreases in stock-based compensation, and investor relations expense.

This decrease was partially

offset by increases in professional fees, depreciation and

amortization and other

general and administrative expenses.

At June 30, 2009, Senesco had cash and

investments of $1.4 million, and working capital of $1.3 million. In

addition, upon the closing

equity financing on July 9,

2009, the Company received

aggregate net proceeds of approximately $900,000. We believe that at the projected rate of

spending and with the proceeds from the private placement completed in July 2009

and the proceeds from the proposed private placement pending NYSE Amex approval,

we should have sufficient cash and investments to maintain our present

operations for the next six (6) months, as of June 30,

Senesco Technologies, Inc.

Senesco Technologies, Inc. is a

U.S. biotechnology company, headquartered in New Brunswick, NJ. Senesco has initiated preclinical

research to trigger or delay cell death in mammals (apoptosis) to determine if

the technology is applicable in human medicine. Accelerating apoptosis may

have applications to development of cancer treatments. Delaying apoptosis

may have applications to certain inflammatory and ischemic

takes its name from the scientific term for the aging of plant cells:

senescence. Delaying cell breakdown in plants extends freshness after

harvesting, while increasing crop yields, plant size and resistance to

environmental stress.

The Company believes that

its technology can be used to develop superior strains of crops without any

modification other than delaying natural plant senescence. Senesco has

partnered with leading-edge companies engaged in agricultural biotechnology and

earns research and development fees for applying its gene-regulating platform

technology to enhance its partners' products.

Certain statements included in this

press release are forward-looking statements within the meaning of the Private

Securities Litigation Reform Act of 1995. Actual results could differ

materially from such statements expressed or implied herein as a result of a

variety of factors, including, but not limited to: the ability of the Company to

consummate additional financings; the development of the Company's gene

technology; the approval of the Company's patent applications; the successful

implementation of the Company's research and development programs and joint

ventures; the success of

the Company's license agreements; the acceptance by the market of the

Company's products; success of the Company's preliminary studies and preclinical

research; competition and the timing of projects and trends in future operating

performance, the Company's ability to comply with the continued listing

standards of the AMEX, as well as other factors expressed from time to time in

the Company's periodic filings with the Securities and Exchange Commission (the

"SEC"). As a result, this press

release should be read in conjunction with the Company's periodic filings with

the SEC. The forward-looking statements contained herein are made

only as of the date of this press release, and the Company undertakes no

obligation to publicly update such forward-looking statements to reflect

subsequent events or circumstances.

CONSOLIDATED STATEMENT OF